243 related articles for article (PubMed ID: 31566325)
1. Who to screen for hepatitis C? A cost-effectiveness study in Belgium of comprehensive hepatitis C screening in four target groups.
Opstaele L; Bielen R; Bourgeois S; Moreno C; Nevens F; Robaeys G; Robaeys G; Van Vlierberghe H
Acta Gastroenterol Belg; 2019; 82(3):379-387. PubMed ID: 31566325
[TBL] [Abstract][Full Text] [Related]
2. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
[TBL] [Abstract][Full Text] [Related]
3. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.
Martin NK; Vickerman P; Brew IF; Williamson J; Miners A; Irving WL; Saksena S; Hutchinson SJ; Mandal S; O'Moore E; Hickman M
Hepatology; 2016 Jun; 63(6):1796-808. PubMed ID: 26864802
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of HCV testing approaches in low and middle income countries.
Morgan JR; Servidone M; Easterbrook P; Linas BP
BMC Infect Dis; 2017 Nov; 17(Suppl 1):697. PubMed ID: 29143681
[TBL] [Abstract][Full Text] [Related]
5. Modelling the Impact and Cost-effectiveness of Extended Hepatitis C Virus Screening and Treatment with Direct-acting Antivirals in a Swiss Custodial Setting.
Girardin F; Hearmon N; Castro E; Negro F; Eddowes L; Gétaz L; Wolff H
Clin Infect Dis; 2019 Nov; 69(11):1980-1986. PubMed ID: 30715266
[TBL] [Abstract][Full Text] [Related]
6. Eradicating hepatitis C: Are novel screening strategies for people who inject drugs cost-effective?
Manca F; Robinson E; Dillon JF; Boyd KA
Int J Drug Policy; 2020 Aug; 82():102811. PubMed ID: 32585583
[TBL] [Abstract][Full Text] [Related]
7. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.
Cortesi PA; Barca R; Giudicatti G; Mossini S; Ciaccio A; Iannazzo S; Micale M; Cesana G; Mantovani LG
Aliment Pharmacol Ther; 2019 May; 49(9):1126-1133. PubMed ID: 30843268
[TBL] [Abstract][Full Text] [Related]
8. The testing of people with any risk factor for hepatitis C in community pharmacies is cost-effective.
Buchanan R; Cooper K; Grellier L; Khakoo SI; Parkes J
J Viral Hepat; 2020 Jan; 27(1):36-44. PubMed ID: 31520434
[TBL] [Abstract][Full Text] [Related]
9. Healthcare value of implementing hepatitis C screening in the adult general population in Spain.
Buti M; Domínguez-Hernández R; Casado MÁ; Sabater E; Esteban R
PLoS One; 2018; 13(11):e0208036. PubMed ID: 30485377
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
[TBL] [Abstract][Full Text] [Related]
11. Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men.
Linas BP; Wong AY; Schackman BR; Kim AY; Freedberg KA
Clin Infect Dis; 2012 Jul; 55(2):279-90. PubMed ID: 22491339
[TBL] [Abstract][Full Text] [Related]
12. Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost-effectiveness analysis.
Girardin F; Hearmon N; Negro F; Eddowes L; Bruggmann P; Castro E
J Viral Hepat; 2019 Feb; 26(2):236-245. PubMed ID: 30338887
[TBL] [Abstract][Full Text] [Related]
13. Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population.
Ethgen O; Sanchez Gonzalez Y; Jeanblanc G; Duguet A; Misurski D; Juday T
J Med Econ; 2017 Feb; 20(2):162-170. PubMed ID: 27590836
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
[TBL] [Abstract][Full Text] [Related]
15. Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea.
Kim DY; Han KH; Jun B; Kim TH; Park S; Ward T; Webster S; McEwan P
PLoS One; 2017; 12(1):e0167770. PubMed ID: 28060834
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
[TBL] [Abstract][Full Text] [Related]
17. Streamlining the screening cascade for active Hepatitis C in Russia: A cost-effectiveness analysis.
Jülicher P; Chulanov VP; Pimenov NN; Chirkova E; Yankina A; Galli C
PLoS One; 2019; 14(7):e0219687. PubMed ID: 31310636
[TBL] [Abstract][Full Text] [Related]
18. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens.
Eckman MH; Ward JW; Sherman KE
Clin Gastroenterol Hepatol; 2019 Apr; 17(5):930-939.e9. PubMed ID: 30201597
[TBL] [Abstract][Full Text] [Related]
19. The cost impact of outreach testing and treatment for hepatitis C in an urban Drug Treatment Unit.
Selvapatt N; Ward T; Harrison L; Lombardini J; Thursz M; McEwan P; Brown A
Liver Int; 2017 Mar; 37(3):345-353. PubMed ID: 27566283
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
Goel A; Chen Q; Chhatwal J; Aggarwal R
J Gastroenterol Hepatol; 2018 Dec; 33(12):2029-2036. PubMed ID: 29864213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]